SG11201500138VA - Etanercept formulations exhibiting marked reduction in sub-visible particles - Google Patents

Etanercept formulations exhibiting marked reduction in sub-visible particles

Info

Publication number
SG11201500138VA
SG11201500138VA SG11201500138VA SG11201500138VA SG11201500138VA SG 11201500138V A SG11201500138V A SG 11201500138VA SG 11201500138V A SG11201500138V A SG 11201500138VA SG 11201500138V A SG11201500138V A SG 11201500138VA SG 11201500138V A SG11201500138V A SG 11201500138VA
Authority
SG
Singapore
Prior art keywords
sub
marked reduction
visible particles
etanercept formulations
formulations exhibiting
Prior art date
Application number
SG11201500138VA
Inventor
Mark Manning
Brian Murphy
Douglas Farrar
Alan Herman
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49916504&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201500138V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of SG11201500138VA publication Critical patent/SG11201500138VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
SG11201500138VA 2012-07-09 2013-07-09 Etanercept formulations exhibiting marked reduction in sub-visible particles SG11201500138VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261669480P 2012-07-09 2012-07-09
US201361806235P 2013-03-28 2013-03-28
PCT/US2013/049778 WO2014011672A1 (en) 2012-07-09 2013-07-09 Etanercept formulations exhibiting marked reduction in sub-visible particles

Publications (1)

Publication Number Publication Date
SG11201500138VA true SG11201500138VA (en) 2015-03-30

Family

ID=49916504

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500138VA SG11201500138VA (en) 2012-07-09 2013-07-09 Etanercept formulations exhibiting marked reduction in sub-visible particles

Country Status (19)

Country Link
US (3) US9662396B2 (en)
EP (2) EP2869816A4 (en)
JP (2) JP6271536B2 (en)
KR (1) KR20150030704A (en)
CN (1) CN104661651A (en)
AU (1) AU2013290289B2 (en)
BR (2) BR112015000203A2 (en)
CA (1) CA2878508A1 (en)
CL (1) CL2015000051A1 (en)
DO (1) DOP2015000006A (en)
EA (1) EA029193B1 (en)
EC (1) ECSP15004752A (en)
HK (2) HK1209343A1 (en)
IL (1) IL236527A0 (en)
IN (1) IN2015KN00005A (en)
MX (1) MX2015000337A (en)
PE (1) PE20150762A1 (en)
SG (1) SG11201500138VA (en)
WO (2) WO2014011672A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012801B1 (en) 2005-06-14 2009-12-30 Эмджен Инк. Self-buffering protein formulations
IN2015KN00452A (en) * 2012-09-11 2015-07-17 Coherus Biosciences Inc
JP2016518386A (en) * 2013-05-02 2016-06-23 マブキシェンス エス．アー． Alternative formulation of TNFR: Fc fusion polypeptide
CN106458999B (en) 2014-03-26 2019-12-03 阿斯特克斯治疗有限公司 Combination
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
JOP20200201A1 (en) 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MX2015010517A (en) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Etanercept composition having improved stability.
WO2017159585A1 (en) * 2016-03-14 2017-09-21 参天製薬株式会社 Antiseptic agent comprising meglumine or salt thereof
EP3528787A4 (en) * 2016-10-21 2020-05-06 Amgen Inc. Pharmaceutical formulations and methods of making the same
CN109937034B (en) * 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 Abutip preparation and application thereof
MX2017013995A (en) * 2017-10-31 2019-05-01 Probiomed S A De C V Stable pharmaceutical formulation of a fusion protein.
KR20200083564A (en) * 2017-11-13 2020-07-08 암젠 인크 How to make protein products
EP3781124A1 (en) * 2018-04-16 2021-02-24 Merck Patent GmbH Method for stabilizing protein comprising formulations by using a meglumine salt
AU2019260418A1 (en) * 2018-04-24 2020-11-19 Amgen Inc. Method for making injectable pharmaceutical compositions
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
TR201808283A2 (en) * 2018-06-11 2018-07-23 Centurion Ilac San Ve Tic A S WATER PHARMACEUTICAL ETHENERSEPT COMPOSITION
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
US20220401365A1 (en) * 2019-10-28 2022-12-22 Astrazeneca Ab Dry powder formulations containing leucine and trileucine
AU2022223669A1 (en) 2021-02-17 2023-08-03 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
JP2003522155A (en) 2000-02-10 2003-07-22 ワイス Methods of treating or inhibiting cell damage or death
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
SI1478394T1 (en) 2002-02-27 2008-12-31 Immunex Corp Stabilized TNFR-Fc composition comprising arginine
CA2515539A1 (en) 2003-02-28 2004-09-10 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
BRPI0413197A (en) 2003-08-01 2006-10-03 Amgen Inc eta wercept crystal; method for making an etanercept crystal; composition; use of an etanercept crystal
CN102020697B (en) * 2003-10-14 2014-10-29 F·霍夫曼-罗须公司 Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2005082377A1 (en) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. INHIBITOR FOR LOWERING IN THE ACTIVITY OF ANTIHUMAN TNF-α ANTIBODY
DK1720972T3 (en) 2004-03-05 2014-04-14 Dsm Ip Assets Bv METHOD OF CELL CULTIVATION USING CONTINUOUS PERFUSION AND ALTERNATIVE TANGENTIAL FLOW
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101584858A (en) * 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 Stable protein formulations
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
JP5374359B2 (en) 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド Stabilized polypeptide compounds
CA2649538C (en) 2006-04-21 2014-06-03 Yatin Gokarn Buffering agents for biopharmaceutical formulations
MX2009003635A (en) 2006-10-06 2009-04-22 Amgen Inc Stable formulations.
AU2007309616B2 (en) 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
LT2170390T (en) 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumab antibody formulations
CA2904458C (en) * 2007-11-30 2017-07-25 Wolfgang Fraunhofer Protein formulations and methods of making same
US20110060290A1 (en) * 2008-02-07 2011-03-10 Amgen Inc. Stabilized protein compositions
MX2010009398A (en) 2008-02-29 2010-11-12 Biogen Idec Inc Purified immunoglobulin fusion proteins and methods of their purification.
CN102159204B (en) * 2008-09-19 2015-04-01 辉瑞公司 Stable liquid antibody formulation
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
EP3431588A1 (en) 2009-08-11 2019-01-23 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
US20120208986A1 (en) 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US9428727B2 (en) 2010-04-26 2016-08-30 Novartis Ag Cell culture medium
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
US20130209465A1 (en) 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
JP2012049074A (en) 2010-08-30 2012-03-08 Makita Corp Battery pack of electric tool
EP2611904A2 (en) 2010-08-31 2013-07-10 Friesland Brands B.V. Culture medium for eukaryotic cells
CA2833427C (en) 2011-04-20 2019-09-24 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein tnfr:fc
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
KR102061355B1 (en) 2011-07-01 2019-12-31 바이오젠 엠에이 인코포레이티드 Arginine-free tnfr : fc- fusion polypeptide compositions and methods of use
WO2013006479A2 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
JP6113176B2 (en) * 2011-10-18 2017-04-12 コヒラス・バイオサイエンシズ・インコーポレイテッド Etanercept formulation stabilized by xylitol

Also Published As

Publication number Publication date
IN2015KN00005A (en) 2015-07-31
AU2013290289B2 (en) 2018-03-29
CN104661651A (en) 2015-05-27
EP2869817A1 (en) 2015-05-13
PE20150762A1 (en) 2015-06-20
IL236527A0 (en) 2015-02-26
EP2869817A4 (en) 2016-04-06
US20150196645A1 (en) 2015-07-16
US20150125532A1 (en) 2015-05-07
KR20150030704A (en) 2015-03-20
BR112015000203A2 (en) 2017-06-27
EP2869816A4 (en) 2016-04-20
EA201590161A1 (en) 2015-07-30
ECSP15004752A (en) 2015-12-31
HK1213174A1 (en) 2016-06-30
EA029193B1 (en) 2018-02-28
US9662396B2 (en) 2017-05-30
US20210007991A1 (en) 2021-01-14
MX2015000337A (en) 2015-09-25
CL2015000051A1 (en) 2015-07-31
WO2014011672A1 (en) 2014-01-16
EP2869816A1 (en) 2015-05-13
CA2878508A1 (en) 2014-01-16
US10822429B2 (en) 2020-11-03
HK1209343A1 (en) 2016-04-01
WO2014011629A1 (en) 2014-01-16
JP2015525763A (en) 2015-09-07
AU2013290289A1 (en) 2015-01-29
BR112015000229A2 (en) 2017-06-27
JP6271536B2 (en) 2018-01-31
JP2015525762A (en) 2015-09-07
DOP2015000006A (en) 2015-05-31

Similar Documents

Publication Publication Date Title
HK1209343A1 (en) Etanercept formulations exhibiting marked reduction in sub-visible particles
IL252566A0 (en) Pharmaceutical compositions and methods
HK1206027A1 (en) Dihydropyrimidine compounds and their application in pharmaceuticals
HK1212034A1 (en) Antibodies to risperidone and use thereof
EP2885418A4 (en) Microcapsule compositions and methods
HK1210714A1 (en) Antibody formulations and uses thereof
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
HK1211862A1 (en) Nanoparticle formulation
EP2884984A4 (en) Therapeutic compositions and methods
HK1209636A1 (en) Trans-clomiphene formulations and uses thereof (trans-clomiphene)
HUE13837694T1 (en) Daptomycin formulations and uses thereof
SG10201606161UA (en) Albumin Formulation and Use
GB201315347D0 (en) Methods and compositions
EP2666482A4 (en) Particle composition and pharmaceutical composition using particle composition
SG11201502069SA (en) Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof
GB201208315D0 (en) Pharmaceutical methods and compositions
EP2834635A4 (en) Heparin-bulking agent compositions and methods thereof
GB201210989D0 (en) Composition and device
IL229936B (en) Albumin formulation and use
GB201810553D0 (en) 18F - Fluciclovine compositions in citrate buffers
GB201113314D0 (en) Formulations and processes